NCT04421963 2026-04-16
ROSY-O
AstraZeneca
Phase 3 Active not recruiting
Clinical Trials
23 trialsNCT06785636 2026-04-07
P300
Pathos AI, Inc.
Phase 1/2 Recruiting
NCT07024784 2026-04-06
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
AbbVie
Phase 2 Recruiting
NCT02693535 2026-04-02
TAPUR
American Society of Clinical Oncology
Phase 2 Recruiting
NCT01042379 2026-03-13
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT07371104 2026-03-05
Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer
Daewoong Pharmaceutical Co. LTD.
Phase 1 Recruiting
NCT02813135 2026-01-16
ESMART
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Recruiting
NCT06116578 2025-12-01
NeoSarc
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Withdrawn
NCT04236414 2025-04-04
Investigating Safety, Tolerability, Efficacy and PK of Olaparib in Paediatric Patients With Solid Tumours
AstraZeneca
Phase 1 Completed
NCT05933265 2025-03-06
Study of LP-184 in Patients With Advanced Solid Tumors
Lantern Pharma Inc.
Phase 1/2 Recruiting
NCT05078671 2024-06-12
PROACTIVE
Radboud University Medical Center
Phase 4 Recruiting
NCT02925234 2024-01-24
DRUP
The Netherlands Cancer Institute
Phase 2 Recruiting
NCT04801966 2023-05-10
TAILOR
Peter MacCallum Cancer Centre, Australia
Phase NA Terminated
NCT02576444 2022-12-28
OLAPCO
Yale University
Phase 2 Terminated
NCT01921140 2022-11-22
To Determine the Effect of Food on the Pharmacokinetics of Olaparib and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours
AstraZeneca
Phase 1 Completed
NCT03239015 2022-03-04
Efficacy and Safety of Precision Therapy in Refractory Tumor
Shanghai Changzheng Hospital
Phase 2 Unknown
NCT03570437 2022-03-02
COPELIA
University of Manchester
Phase 2 Unknown
NCT04566952 2020-10-30
ANLOLA
Jiangsu Cancer Institute & Hospital
Phase 2 Unknown
NCT02093351 2019-10-02
To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer
AstraZeneca
Phase 1 Completed
NCT00678132 2018-07-05
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT01813474 2018-01-16
Investigate the Safety and Tolerability of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies
AstraZeneca
Phase 1 Completed
NCT01851265 2017-08-28
D081AC00001 Food Interaction With Olaparib Capsule in Patients With Solid Tumours
AstraZeneca
Phase 1 Completed
NCT00572364 2009-08-20
Open Label, Dose Escalation Phase I Study of AZD2281
AstraZeneca
Phase 1 Completed